Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Tg Therapeutics (NQ: TGTX )

34.41 -0.14 (-0.41%)
Streaming Delayed Price Updated: 11:45 AM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Tg Therapeutics

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
A Closer Look at TG Therapeutics's Options Market Dynamics
Via Benzinga
NASDAQ:TGTX stands out as a growth opportunity that won't break the bank.
NASDAQ:TGTX is showing decent growth, but is still valued reasonably. 
Via Chartmill
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Stock Market Surges To Highs On Trump Election; Fed Cuts Rates, Palantir Soars: Weekly Review
A Fed rate cut and a slew of big earnings reports filled out a busy week. 
Via Investor's Business Daily
Topics Economy Government
Exposures Interest Rates Political
The Analyst Verdict: TG Therapeutics In The Eyes Of 5 Experts
Via Benzinga
Delving into NASDAQ:TGTX's Growth Prospects.
Why TG THERAPEUTICS INC (NASDAQ:TGTX) qualifies as a high growth stock. 
Via Chartmill
Why NASDAQ:TGTX qualifies as a high growth stock.
Is TG THERAPEUTICS INC (NASDAQ:TGTX) suited for high growth investing? 
Via Chartmill
TG Therapeutics Crashes — Reversing A Breakout — On Its Mixed Third-Quarter Results
The company raised its sales outlook for the year, though, following stronger-than-expected revenue from its only product. 
Via Investor's Business Daily
Why Yum China Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Napco Security Technologies Posts Downbeat Results, Joins Centrus Energy, Constellation Energy And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
10 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Unlocking the Growth Potential of NASDAQ:TGTX.
TG THERAPEUTICS INC (NASDAQ:TGTX) may be suited for growth investing, we'll explore why in this article. 
Via Chartmill
Evaluating TG Therapeutics: Insights From 4 Financial Analysts
Via Benzinga
What's Going On With TG Therapeutics Stock Wednesday?
TG Therapeutics announced it updated its data presentations to include details from the ULTIMATE I & II Phase 3 trials. 
Via Benzinga
AI Stocks Meta, Oracle Lead Five Names Near Buy Points
Two of the 5 top stocks to watch this week tap the artificial intelligence market. 
Via Investor's Business Daily
Topics Artificial Intelligence
Exposures Artificial Intelligence
As Stock Market Awaits Election, Palantir, S&P 500 Nuke Leaders Report
Amid the election, and a Fed rate vote, earnings season roars ahead. 
Via Investor's Business Daily
Topics Economy Stocks
Exposures Interest Rates US Equities
Investors seeking growth at a reasonable cost should explore NASDAQ:TGTX.
TG THERAPEUTICS INC (NASDAQ:TGTX) stands out as a growth opportunity that won't break the bank. 
Via Chartmill
NASDAQ:TGTX—Positioned as a High-Growth Stock, Ready for a Potential Breakout.
TG THERAPEUTICS INC (NASDAQ:TGTX)—Positioned as a High-Growth Stock, Ready for a Potential Breakout. 
Via Chartmill
For those who appreciate growth without the sticker shock, NASDAQ:TGTX is worth considering.
NASDAQ:TGTX is showing decent growth, but is still valued reasonably. 
Via Chartmill
Why NASDAQ:TGTX is Poised for High Growth.
Exploring TG THERAPEUTICS INC (NASDAQ:TGTX)'s growth characteristics. 
Via Chartmill
In the world of growth stocks, NASDAQ:TGTX shines as a value proposition.
NASDAQ:TGTX, a growth stock which is not overvalued. 
Via Chartmill
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Stock Market Hits Record Highs On Big Fed Rate Cut; Apple, Intel, FedEx In Focus: Weekly Review
TheApple iPhone 16 went on sale amid mixed signals about demand. 
Via Investor's Business Daily
Topics Economy
Exposures Interest Rates
IBD 50's TG Therapeutics Surges On Five-Year Data For Multiple Sclerosis Drug
The company unveiled five-year test results for its multiple sclerosis drug, Briumvi. 
Via Investor's Business Daily
Despite its growth, NASDAQ:TGTX remains within the realm of affordability.
While growth is established for TG THERAPEUTICS INC (NASDAQ:TGTX), the stock's valuation remains reasonable. 
Via Chartmill
NASDAQ:TGTX—Positioned as a High-Growth Stock, Ready for a Potential Breakout.
TG THERAPEUTICS INC (NASDAQ:TGTX)—Positioned as a High-Growth Stock, Ready for a Potential Breakout. 
Via Chartmill
What's Going On With ADMA Biologics Stock Monday?
ADMA Biologics shares are moving higher after it was announced that the company will join the S&P SmallCap 600. 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
IBD 50 Stock TG Therapeutics Breaks Out Bullishly After 'Solid' Quarter
The company reported a surprise profit in the second quarter, vs. expectations for losses. 
Via Investor's Business Daily
ZIM Integrated Shipping Services Posts Upbeat Earnings, Joins fuboTV, Foghorn Therapeutics And Other Big Stocks Moving Higher On Monday
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.